Trastuzumab + Pertuzumab (HP) maintenance, HER2+ metastatic breast post-THP induction
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TRASTUZUMAB DRUG-PERTUZUMAB |
|---|
| ID | REG-HP-MAINTENANCE |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Notes
CLEOPATRA (Swain 2020, NEJM): pertuzumab + trastuzumab + docetaxel vs trastuzumab + docetaxel — mOS 57.1 vs 40.8 mo. After ~6 cycles of THP induction with confirmed response, docetaxel is dropped and HP maintenance continues until progression. Endocrine therapy added if HR-co-positive. PHESGO (HP fixed-dose SC + hyaluronidase) approved alternative — single SC injection over ~5-8 min, replaces both IV infusions; preferred for chair-time and patient convenience after initial IV doses tolerated. LVEF baseline + q3 mo.
Used By
Indication
IND-BREAST-HER2-POS-MAINT-TRAST- IND-BREAST-HER2-POS-MAINT-TRAST